Liver cancer is a major cause of premature death in many areas of Africa and Asia and its incidence is strongly correlated with exposure to aflatoxin B1 (AFB1).
P450I1A in the activation of AFBI by human liver microsomes.
This hypothesis was strongly supported by the finding that antibodies to P4501A2 and P45011A1 were also effective inhibitors of metabolism in many of the samples. These data demonstrate that, although P450I1A probably plays an innportant role in AFBI activation, several other cytochrome P-450 forms have the capacity to activate the toxin. Similar considerations apply to detoxifying metabolism to aflatoxin Qi and aflatoxin M1. The levels of expression of many of the forms of cytochrome P450 involved in AFBI metabolism are known to be highly sensitive to environmental factors. This indicates that such factors will be an important determinant in individual susceptibility to the tumorigenic action of AFBI.
Liver cancer is one of the major causes of premature death in certain regions of Africa and Asia. Two major environmental factors have been implicated in the etiology of this disease: infection with hepatitis B virus and exposure to the chemical carcinogen aflatoxin B1 (AFB1) (1, 2) . AFB1 is a mycotoxin produced by species of Aspergillus, and human exposure results principally from the ingestion of stored foodstuffs contaminated with the mold. The carcinogenicity of this compound is associated with its conversion to aflatoxin 8,9-oxide by the hepatic cytochrome P-450 (P450)-dependent monooxygenase system (3, 4) . It is therefore of considerable importance to establish which human P450 isozymes are involved in the metabolism of this compound and to understand the genetic and environmental factors which determine their level of expression.
In animal model systems, evidence for the involvement of a wide variety of P450 isozymes, from several gene families, in the metabolism of AFB1 has been forthcoming. These include proteins from the 3-methylcholanthrene-inducible family P4501A (5) (6) (7) , the phenobarbital-inducible P450IlB subfamily (8, 9) , and P450IIC subfamily (10) , the dexamethaxone-inducible P450IIIA family (11) , and possibly P450s from the family P450IVB (8) .
The complexity of the rodent system does not permit easy identification of candidate human P450s involved in the activation and metabolism of this compound. Induction of specific AFB1 metabolic pathways in rodents, however, has indicated the catalytic roles played by the induced P450 species. The administration of polycyclic hydrocarbons induces predominantly 4-hydroxylation, forming aflatoxin Ml (AFM1), and to a much lesser extent epoxidation, whereas phenobarbital induces epoxidation and aflatoxin Q, (AFQ1) formation to approximately equal extents (12) . In the case of human microsomes, Shimada and Okuda (11) concluded that constitutively expressed forms were probably involved in AFB1 activation. They excluded cytochromes from the P450IA and P45OIIB gene families, as antibodies raised against the rat homologues of these proteins did not inhibit AFB1 metabolism in human liver. Studies using immunochemical inhibition indicated that the P450 associated with the polymorphic metabolism of debrisoquine, subfamily P450IID, was also not involved in the metabolism of AFB1 either to a DNA-binding species or to AFQ1 (13). Shimada and Guengerich (14) have recently reported that the major cytochrome P450 associated with AFB1 activation is a member of the P450IIIA family, a protein also associated with the oxidation of nifedipine. Their evidence was based principally on correlations between level of the P450IIIA cytochrome and the rate of AFB1 metabolism to mutagenic products or products that bound to DNA. However, their experiments using reconstituted cytochrome systems indicated that the activation of AFB1 to mutagenic species was not confined to P450IIIA, although this enzyme had the highest activity of the three tested. These workers selected a single liver sample for further study, and found a surprisingly high activity towards sterigmatocystin (>2 x the activity towards AFB1) and a very low activity towards aflatoxin G1 (AFG1). This is unexpected in view of the potent carcinogenic and toxic properties of AFG1 and the low carcinogenicity of sterigmatocystin noted in animal experiments. Since Preparation and Use of Antisera. Antibodies were raised against purified rat P450 isozymes as previously described (16) (17) (18) . When used as inhibitors, antibodies (IgG fraction) at various concentrations were incubated with the microsomal samples at room temperature for [15] [16] [17] [18] [19] [20] Proteins identified in human liver by using antibodies raised to rat liver P450 proteins. Microsomal proteins from a single human liver (7.5 ug per track) were loaded across a 7% polyacrylamide slab gel and separated by electrophoresis. The proteins were transferred to nitrocellulose and the filter was inserted into an apparatus that allows simultaneous exposure to several P450 antibodies without cutting the nitrocellulose sheet (Decca probe; Hoefer). The antibodies used were raised to the following rat liver P450s: P4501A2, P45011A1, P45011B1, P45011C6, P4501ID6 (human monoclonal antibody), P45011E1, P450111A1, and P450IVA1 (see ref.
19 for the nomenclatures used). The estimated molecular masses are given in Table 2 . Samples P45011B and P450IVA were run on a separate gel. The antibodies used reacted specifically with recombinant human P450s from the gene families to which the antibodies were raised and, on the basis of relative mobility in SDS gels, the P450s were categorized according to the nomenclature of Nebert et al. (19) as: P450IIAii = P45011A3, P45011B = P45011B6, P450IICi = P45011C9, P450IICii = P45011C8, and P450111A = P450111A3 or P450111A4. These latter two recombinant proteins reacted with the antibody to P450IIIA1 and have the same mobility on SDS gels. protein bands were identified. This is consistent with the reports of the expression of multiple members of this gene family in human liver (20) and the isolation of cDNA clones encoding several distinct proteins (21) . Where possible, antibody specificity was demonstrated by showing specific reactivity with the expressed recombinant P450 proteins (a generous gift of Dr. F. Gonzalez). The recombinant proteins also had the same electrophoretic mobilities as the proteins identified in the microsomes by Western blot analysis (see legend to Fig. 1 ).
Immunoblotting. Microsomal samples (7.5 Ag) were separated by SDS 9% polyacrylamide gel electrophoresis, transferred to nitrocellulose, and exposed to the P450 antibodies (1:500 dilution) as previously described (22, 23 7.4 . The mixture was poured onto prepoured agar plates (Difco) immediately after the addition-of 5 ,uM AFB1, 0.1 ml of an overnight culture of Salmonella typhimurium strain TA98, and 2 ml of 0.6% agar containing 0.6% NaCl, 50 JIM L-histidine hydrochloride, 50,uM biotin, and ampicillin at 250 ,ug/ml. Plates, in triplicate, were incubated for 48 hr at 37°C.
The bacterial strain was routinely tested for ampicillin resistance, histidine requirement, and deep rough character (tested by using crystal violet) and with reference mutagens in discs impregnated with 10 ,ul of sodium azide at 100 ,ug/ml, 4-nitro-o-phenylenediamine at 600 ug/ml, or nitrofurantoin at 10 ,g/ml as described by Zeiger et al. (27) . Mutation frequency was determined from the number of histidineindependent revertant colonies. RESULTS P450 isozyme levels in a range of human liver samples, determined by Western blotting, were compared with the ability of the samples to metabolize AFB1 to products mutagenic to S. typhimurium, to the carcinogenic AFB1 8,9-epoxide (assayed as AFB1 8,9-dihydrodiol), and to the detoxification products AFQ1 and AFM1. Both AFQ1 and AFBj 8,9-dihydrodiol were produced in significant amounts by the human liver samples and represented up to 80% of the total soluble metabolites formed with lower amounts of AFM1 (Table 1) . Of the P450 forms detected by Western blot analysis ( Fig. 1) there was a high correlation between AFBj metabolism to the carcinogenic AFB1 8,9-epoxide (assayed as AFB1 8,9-dihydrodiol) and the microsomal content of P450IIIA3/P450IIIA4 (Table 2) . Interestingly, the formation of AFQ1, an AFB1 detoxification product, also correlated strongly with the expression of these proteins (Table 2) . It is perhaps significant that the formation of these products was also highly correlated with the total P450 content. The expression of P450IIIA3/P450IIIA4, as well as total P450 8308 Biochemistry: Forrester et al. content, was also highly correlated with AFB1-induced mutation rate (Fig. 2, Table 2 ). In the 19 liver samples studied, the level of P450IIIA protein was subject to a 26-fold variation, compared with a 13-fold variation in mutation frequency and a 5-fold variation in the rate of AFB1 8,9-dihydrodiol formation.
For the liver panel shown in Table 2 AFB1-induced mutagenicity and metabolism to the AFB1 8,9-dihydrodiol and AFQ1 also correlated with the level of a protein in the P450IIC gene subfamily (band P450IICii, P4501IC8). In further studies, using a second panel of human liver microsomes, the high correlation with P450IIIA3/P450IIIA4, as well as P450 content, was confirmed. A correlation with a member of the P450IVA family (band P450IVAiii, P < 0.05) was also observed (results not shown). In this panel the association of metabolic activation with the level ofP450IIC8 protein did not reach statistical significance. In these latter studies the metabolism ofAFB1 to AFM1 also correlated with the expression ofwhat appears to be P450IA2 (P < 0.05) (data not shown).
The above data indicated that several human P450 forms have the capacity to metabolize and activate AFB1. The The antibody to P450IIIA1 was found to be a potent inhibitor of AFB1-induced mutagenesis in all of the liver samples tested, irrespective of the capacity of the individual microsome samples to metabolize the compound to mutagenic products (Figs. 2 and 3) . In all four of the liver samples that were used to give the results detailed in Fig. 3 , more than 80o inhibition of mutagenicity was observed at the highest concentration of IgG used. In two separate experiments using human liver microsomal preparations, anti-P450IIIA1 was found to be an inhibitor of AFB1 metabolism to AFB1 between 50o and 100%. In addition, inhibition was also observed in many of these samples with an antibody to P4501A2 and ranged between 0% and 62%. This antibody also inhibited AFB,-induced mutagenicity in liver L5 by 54% (Fig.   3 ). The slight differences in the ability of P450IA2 or P450IIIA1 antibodies to inhibit 7,8-diol formation vs. AFB1 mutagenicity (Fig. 4 vs. Fig. 5 drodiol formation in some samples (Fig. 5) . Significant variability in the effectiveness ofthis antibody was observed. The inhibition ranged between 13% and 47%. These data support the involvement of multiple forms of P450 in AFB1 metabolism in human liver. There did not appear to be a direct relationship between the level of P450IA2 or P450IIA3 proteins and the ability of antibodies to these cytochromes to inhibit AFB1 metabolism. Also, it might have been expected that inhibition by P450IA2 or P450IIA1 antibodies would be observed in samples containing low levels of P450IIIA protein. However, this was not the case. It is worthy of note that the summed antibody inhibition of metabolism or mutagenesis, resulting from the use of all the antibodies in a single liver microsomal preparation, in some cases exceeded 100%6. The reason for this is unclear. However, similar observations have been made in other P450 antibody inhibition and immunoquantitation studies.
DISCUSSION
We provide evidence that proteins from several distinct human P450 gene families have the capacity to metabolize AFB1 to both mutagenic products and the carcinogenic 8,9-epoxide. The most consistent and potent inhibitor of AFB1 metabolism and mutagenicity was an antibody to a member of the P450IIIA gene family. This antibody recognizes three distinct recombinant human P450IIIA proteins. Two, which are highly homologous at the amino acid level (P450IIIA3 and P450111A4), have the same mobility as the protein identified in human liver by Western blot analysis (L.M.F., F. J. Gonzalez, and C.R.W., unpublished data). The involvement of proteins encoded by the P450IIIA gene family in AFB1 activation is in agreement with the findings of Shimada and Guengerich (14) . The P450 identified by these workers (P450IIIA4) catalyzes the oxidation of the calcium channel-blocking drug nifedipine. The finding that the metabolic activation of AFB1 is also highly correlated with the total P450 content indicates that P450IIIA proteins are often the major P450 forms in human liver. Indeed, analysis of our data shows that in the two liver panels used in this study the expression of P450IIIA was significantly correlated with total P450 content, with correlation coefficients (RJ) of 0.92 (P < 0.005) and 0.56 (P < 0.05). This indicates that the correlation between P450IIIA3/P450IIIA4 expression and AFB1 metabolism is because it is present in high concentration and not because it is the only P450 with the capacity to metabolize this substrate. The potential of other P450s to metabolize AFB1 is substantiated by the inability of P450IIIA1 antibody to completely inhibit metabolism in many of the liver samples and by the finding that antibodies to P450IIA1 and particularly P4501A2 were effective inhibitors of 8,9-diol formation.
Current evidence indicates that the toxic or carcinogenic effects of AFB1 are intimately linked to both the rate of activation and the rate of detoxification at both the primary and secondary levels of metabolism (30) . Primary detoxification by metabolism conversion to AFQ1 appears also to be catalyzed predominantly by proteins of the P450IIIA gene family. Whether P450IIIA3, P450IIIA4, or both proteins are involved in both the metabolic activation and the formation of the AFQ1 remains to be determined. It is worthy of note that these two pathways of AFB1 metabolism are coinduced in the rat by treatment with phenobarbital (12) . It is also interesting that the formation of AFB1, a further detoxification product, was correlated with the expression of P450IA2.
Our studies strongly support the conclusion that although P450s in the P450IIIA gene family play an important role in the activation of AFB1 other species of cytochrome can play a major role. The variability in the relative role of different enzymes is probably due to the large variation in their level of expression. Studies (31) . Hepatic levels of members of the P450IIIA gene family are regulated by glucocorticoids and a wide variety offoreign compounds (32) . Recent studies have also indicated that in the mouse P450IIA proteins are highly inducible by pyrazole and to a lesser degree by phenobarbital (33) . It is interesting that P450IIA proteins catalyze coumarin hydroxylation (34, 35) and that AFB1 also contains the coumarin structure. The apparent inducibility of many of the P450s involved in AFB1 metabolism suggests that the relative importance of specific forms in its activation will be determined by environmental and/or hormonal factors. Whether genetic factors are also involved remains to be established.
A genetic polymorphism in the P450IID6 in humans, which results in a loss of the function of this protein, has been associated with reduced susceptibility to liver cancer (36) . This indicates that this P450 is involved in the activation of liver carcinogens. However, no correlation between AFB1 activation or AFQ1 metabolism and the level of P450IID6 protein was found (Table 2) . Indeed, in individual livers not expressing this enzyme metabolism was often high-e.g., liver L7 (Table 1) . Wolffet al. (13) have also shown that in rats antibodies to P450IlD proteins do not inhibit AFB1 activation or detoxification. The lack of correlation between the genetic and biochemical data is difficult to reconcile unless other factors are involved in the disease association observed.
Evidence for the involvement of AFB1 in the pathogenesis of liver cancer in humans is strong but circumstantial. Identification of the cytochrome P450s involved in the pathways of AFB1 metabolism may help elucidate factors that contribute to susceptibility to this disease.
